INTRODUCTION
============

The presence of metastasis in the stomach is rare, with a reported incidence of 0.2% to 1.7% according to clinical and autopsy findings.[@b1-gnl-09-615],[@b2-gnl-09-615] Previous studies report that lung, breast, melanoma, and esophageal carcinomas can metastasize to the stomach, even though the risk is very low.[@b3-gnl-09-615],[@b4-gnl-09-615] The mechanisms underlying gastric metastasis have not been clearly elucidated and are probably different for every primary tumor. Four pathways may be involved in the metastatic spread of the original primary cancers to the stomach: peritoneal dissemination, hematogenous dissemination, lymphatic spread, and direct tumor invasion.[@b5-gnl-09-615]

Generally, patient prognosis and survival outcome are poor because the presence of gastric metastasis is associated with advanced disease.[@b6-gnl-09-615] However, there are very few case reports on metastatic cancer in the stomach due to their low incidence.[@b7-gnl-09-615],[@b8-gnl-09-615] Clinical outcomes of metastatic tumor to the stomach are not reported yet. In this study, we gathered and reviewed the data on the patients with metastasis in the stomach in order to show the clinicopathologic features, clinical outcomes and prognostic factors.

MATERIALS AND METHODS
=====================

1. Patients
-----------

Between January 1995 and December 2012, a total of 26,424 patients with gastric malignancy visited Asan Medical Center. Patients without endoscopic findings in their medical records or histological confirmation, and patients with leukemia, malignant lymphoma, or direct invasion from adjacent organs, were excluded from the analysis. Finally, there was a total of 37 patients diagnosed with metatstatic tumors in the stomach. The medical records of these patients were retrospectively reviewed. This study was approved by the Institutional Review Board of Asan Medical Center.

2. Endoscopic patterns of metastatic lesions in the stomach
-----------------------------------------------------------

Esophagogastroduodenoscopy (EGD) was used for the diagnosis, and all the lesions were confirmed using endoscopic biopsy followed by histological analysis. Collected data included epidemiological characteristics, symptomatology, indications for endoscopic investigation, macroscopic presentation, time between primary tumor diagnosis and the detection of gastric metastasis, and treatment. Endoscopic procedures were performed using a single-channel endoscope (GIF-H260; Olympus Optical Co., Ltd., Tokyo, Japan). Using standard biopsy forceps, biopsies were obtained from suspected lesions under direct-vision endoscopy. Two endoscopists (J.Y.A. and H.Y.J.) reviewed the endoscopic findings and categorized the gross findings into two main patterns: resembling submucosal tumor or resembling primary gastric cancer. Those resembling primary gastric cancer were subdivided into two groups: resembling early gastric cancer and resembling advanced gastric cancer ([Fig. 1](#f1-gnl-09-615){ref-type="fig"}). Those resembling advanced gastric cancer were further subdivided into four types. Type 1 is a polypoid tumor. Type 2 is an ulcerated tumor with sharply demarcated margins. Type 3 is an ulcerated tumor without definite borders. Type 4 is diffusely infiltrating tumor.

3. Histologic patterns of metastatic lesions in the stomach
-----------------------------------------------------------

The histological results were reviewed by the pathologists. The biopsy specimens were carefully studied and compared with the histological features of the primary tumors.

4. Statistical analysis
-----------------------

Categorical variables were analyzed using the Fisher exact test. The Mann-Whitney U test was used for continuous variables. Continuous variables are presented as median values with the interquartile range (IQR), and the categorical variables are presented as numbers with percentages. The Kaplan-Meier method and log-rank test were used to evaluate differences in overall survival. All p-values are two-sided, and p\<0.05 was considered statistically significant. All statistical analyses were performed using SPSS version 21.0 (SPSS Inc., Chicago, IL, USA).

RESULTS
=======

1. Baseline characteristics of patients with metastatic tumors in the stomach
-----------------------------------------------------------------------------

The baseline characteristics of the patients are summarized in [Table 1](#t1-gnl-09-615){ref-type="table"}. The study population consisted of 21 male and 16 female patients (median age, 57.0 years; IQR, 49.5 to 61.0 years). The chief clinical manifestations of these 37 cases were gastrointestinal bleeding (12 cases, 32.4%), abdominal pain (6 cases, 16.2%), dysphagia (3 cases, 8.1%), and vomiting (2 cases, 5.4%). Another 11 patients had no symptoms. The endoscopic findings showed that solitary metastases (23 cases, 62.2%) were more common than multiple metastases (14 cases, 37.8%). The median interval between the diagnosis of the primary tumor and the diagnosis of the metastatic tumor in the stomach was 13.5 months (IQR, 0.75 to 33.5 months).

2. Sites of the primary tumors
------------------------------

As indicated in [Table 2](#t2-gnl-09-615){ref-type="table"}, the most common primary malignancy that lead to metastatic tumors in the stomach was malignant melanoma (10 cases, 27.0%), followed by lung cancer (7 cases, 18.9%), breast cancer (5 cases, 13.5%), esophageal cancer (3 cases, 8.1%), colorectal cancer (2 cases, 5.4%), ovarian cancer (3 cases, 8.1%), kidney cancer (3 cases, 8.1%), head and neck cancer (1 case, 2.7%), bladder cancer (1 case, 2.7%), choriocarcinoma (1 case, 2.7%), and neuroblastoma (1 case, 2.7%). Among melanoma cases, the confirmed primary tumor site was the skin in 6 cases, but the primary site could not be determined in 4 cases. Among 7 lung cancers, 4 squamous cell carcinoma, 2 adenocarcinomas, and 1 epithelioid tumor were identified.

3. Endoscopic appearance of metastatic tumors in the stomach
------------------------------------------------------------

[Table 3](#t3-gnl-09-615){ref-type="table"} shows the endoscopic appearance of the metastatic tumors in the stomach, which were divided into two groups. The first group resembled submucosal tumors (12 cases, 32.5%), and the second group (25 cases, 67.5%) resembled primary gastric cancer. Among patients with metastasis that resembled early gastric cancer, 2 breast cancers, 2 lung cancers, 1 malignant melanoma, 1 head and neck cancer, and 1 esophageal cancer were identified. Among patients with metastasis that resembled advanced gastric cancer, 3 malignant melanomas, 3 lung cancers, 2 kidney cancers, 3 ovary cancers, 2 colorectal cancers, 2 esophageal cancers, 1 choriocarcinoma, 1 neuroblastoma, and 1 breast cancer were identified. Although gastric metastases may be recognized as abnormalities on EGD, there are no characteristic features that can be used to identify this disease because of the variable morphology of the tumors.

4. Clinical outcomes of metastatic tumors in the stomach according to treatment
-------------------------------------------------------------------------------

The clinical data of the 37 study patients are summarized in [Table 4](#t4-gnl-09-615){ref-type="table"}. Only 12 patients received some form of treatment after the diagnosis of gastric metastasis. Surgical resection was performed on six patients. Partial gastrectomy for metastasis from lung cancer was performed on two patients, and wedge resection with chemotherapy was performed on one patient with metastatic malignant melanoma. Two patients with esophageal cancer and stomach metastasis underwent partial gastrectomy with concurrent chemoradiotherapy. One patient with renal cell carcinoma with stomach metastasis underwent wedge resection because of uncontrolled cancer bleeding. The median survival period of the 37 patients was 18.0 months (IQR, 6.0 to 18.0 months) after the diagnosis of primary cancer. Survival after the diagnosis of gastric metastasis was 3.0 months (IQR, 1.0 to 11.0 months) ([Table 5](#t5-gnl-09-615){ref-type="table"}).

Among the 12 patients who received treatment, the median survival period after the diagnosis of metastatic cancer and the median survival period after the diagnosis of primary cancer were longer than the 25 patients who did not receive treatment (11.0 months \[IQR, 9.0 to 30.0 months\] vs 2.0 months \[IQR, 1.0 to 11.0 months, p\<0.001\]; 60.0 months \[IQR, 18.0 to 85.0 months\] vs 14.0 months \[IQR, 5.0 to 32.0 months\], respectively; p=0.022) ([Fig. 2A](#f2-gnl-09-615){ref-type="fig"}).

5. Clinical outcomes of solitary metastatic tumors and multiple metastatic tumors in the stomach
------------------------------------------------------------------------------------------------

Among all 37 patients, solitary metastatic tumors in the stomach were found in 23 patients (62.2%) and multiple lesions in 14 patients (37.8%). Among patients with solitary metastasis, six patients underwent gastrectomy. Four of these patients received systemic chemotherapy after surgery. [Table 6](#t6-gnl-09-615){ref-type="table"} summarizes of the clinical factors in comparison with patients with a solitary lesion and patients with multiple lesions. Patients with a solitary lesion demonstrated longer median survival after the diagnosis of metastatic cancer than patients with multiple lesions (7.0 months \[IQR, 2.0 to 13.0 months\] vs 2.0 months \[IQR, 1.0 to 6.0 months\], as respectively; p=0.047). Kaplan-Meier survival curves show that patients with a solitary lesion demonstrated better prognosis than patients with multiple lesions ([Fig. 2B](#f2-gnl-09-615){ref-type="fig"}).

DISCUSSION
==========

The stomach is an unusual site for metastasis. As a rare condition, the actual incidence of metastasis to the stomach is difficult to assess. Only 0.2% to 1.7% of cancer patients with metastatic disease reportedly develop metastasis in the stomach, and this diagnosis is typically made at autopsy.[@b1-gnl-09-615],[@b7-gnl-09-615] However, because the prognosis of cancer patients has gradually improved, gastric metastasis is encountered more frequently. Moreover, there has been not enough studies about the clinical outcomes about the metastatic tumor to the stomach, especially about the endoscopic features and the proper treatment to the patients. The study shows that patients with solitary lesions and patients who receive treatment demonstrate longer survival after the diagnosis of metastatic cancer than patients with multiple lesions and patients who have not received treatment (7 months vs 2 months \[p=0.047\] and 11 months vs 2 months \[p\<0.001\]). Based on these results, administration of proper treatment to select patients, especially those with solitary metastatic lesions, can offer the chance of a longer term survival despite poor overall prognosis and heterogeneity of the primary tumors.

The management of gastric metastasis varies depending on the treatment method. Success has been documented using several approaches, including surgery, endoscopy, radiotherapy, chemotherapy, and hormonal therapy.[@b8-gnl-09-615] Because the presence of gastric metastasis is associated with advanced disease, the survival period is extremely short and treatment for metastatic tumors in the stomach usually consists of systemic therapy rather than surgery.[@b9-gnl-09-615] However, in patients with a solitary metachronous gastric metastasis, the surgical resection of metastatic gastric tumors may be recommended in order to control hemorrhage and solitary metastasis in the stomach may be removed using minimally invasive methods such as endoscopic mucosal resection.[@b10-gnl-09-615],[@b11-gnl-09-615] In the present study, surgical resection, such as partial gastrectomy or wedge resection, was performed on six patients. Surgical resection was performed on another six patients, partial gastrectomy of metastasis from lung cancer was performed on two patients, and wedge resection with chemotherapy was performed on one patient with metastatic malignant melanoma. Two patients with esophageal cancer and stomach metastasis received partial gastrectomy with concurrent chemoradiotherapy. One patient with renal cell carcinoma and stomach metastasis received wedge resection because of uncontrolled cancer bleeding. Interestingly, five of six patients who received surgery survived \>1 year following treatment. Such outcomes may suggest that aggressive treatment strategies may benefit to patients who have with appropriate conditions for the treatment.

In a previous study, solitary metastases were reported to be more common than multiple metastases, and lesions were mainly located in the body of the stomach.[@b3-gnl-09-615] In the present study, solitary metastases (23 cases, 62.2%) were found to be more common than multiple metastases (14 cases, 37.8%). Among our study patients with a solitary lesion, 14 cases (60.9%) developed metastasis in the body of the stomach and nine patients (39.1%) developed metastasis in another part of stomach. Of the patients with multiple lesions, eight (57.1%) developed metastasis in the body of the stomach and six patients (42.9%) developed metastasis in another part of stomach, thereby corroborating similar observations by Oda *et al*.[@b3-gnl-09-615] However, there have been no studies that compared the clinical outcomes of solitary and multiple lesions. The present study shows that patients with a solitary lesion demonstrate a longer median survival after the diagnosis of metastatic cancer than patients with multiple lesions (7.0 months vs 2.0 months, p=0.047). Therefore, in the absence of widely metastatic disease in patients with the proper conditions for surgery, aggressive therapy may offer the chance of long-term survival to patients with solitary metastasis.

Most patients with metastatic tumors in the stomach are asymptomatic. The symptoms of metastatic tumors, including pain, nausea, vomiting, and signs of bleeding, are nonspecific.[@b12-gnl-09-615] Iron-deficiency anemia and a guaiac-positive stool may also present.[@b13-gnl-09-615] In a previous autopsy series, abdominal pain was the most common symptom followed by nausea, vomiting, anorexia, and acute upper gastrointestinal bleeding. The current study shows that gastrointestinal bleeding (12 cases, 32.4%) is the most common presentation, and endoscopy is an important diagnostic tool for evaluating metastatic lesions as well as evaluating the results of therapeutic intervention. Accordingly, we believe that endoscopic examination and histologic evaluation should be performed to identify any metastatic gastrointestinal lesions in patients with known primary cancer and symptoms related to gastrointestinal tracts, especially abdominal pain and gastrointestinal bleeding.

In metastatic cancers to the stomach, three main morphological features of endoscopic findings have been reported: nonulcerative masses, submucosal tumor masses with elevation and ulceration at the apex (volcano lesions), and multiple nodules of varying sizes with tip ulceration.[@b14-gnl-09-615] Rarely, some lesions may appear as raised plaques, fat ulcers, or thickened walls. In our present study, submucosal tumors and polypoid masses were common endoscopic features. This finding is considered to be related with hematogenous dissemination and lymphatic spread of the primary tumor through the submucosal layer being the main metastatic pathway. Therefore, when submucosal tumors and polypoid masses are found in patients with malignancy, thorough endoscopic scrutinzation with biopsies and careful history taking should be conducted to improve diagnostic accuracy of gastric metastasis.

The mechanisms underlying gastric metastasis have not been clearly elucidated and are most likely different for each primary tumor. There are four pathways that may be involved in the metastatic spread of original primary cancers to the stomach: peritoneal dissemination, hematogenous dissemination, lymphatic spread, and direct tumor invasion.[@b5-gnl-09-615] Previous studies reveal that the breast and lung are the most common primary sites, which may reflect the high incidences of these tumors in the general population.[@b3-gnl-09-615] In malignant melanoma, the incidence of gastric metastasis is high because of the high tropism of the tumor to the gastrointestinal tract. According to the literature, about half of all patients with gastric metastasis concomitantly demonstrate metastatic lesions in other organs and the mean time from the diagnosis of gastric metastasis to death is approximately 4.75 months.[@b15-gnl-09-615] In the present study, the most common primary lesion was found to be melanoma followed by lung cancer (7 cases, 18.9%), breast cancer (5 cases, 13.5%), esophageal cancer (3 cases, 8.1%), colorectal cancer (2 cases, 5.4%), ovarian cancer (3 cases, 8.1%), and kidney cancer (3 cases, 8.1%). Similar results have been reported in an earlier study in which the majority of the primary tumors included breast carcinoma, melanoma, and lung neoplasm.[@b3-gnl-09-615] Of these, half of metastatic tumors were found within a year of the diagnosis of the primary tumors (14.0 months \[IQR, 0.5 to 48.0 months\]). Endoscopic examinations should be carefully conducted and gastric metastasis should be considered for patients with melanoma, lung cancer, or breast cancer, especially when symptoms are evident.

The current study has limitations due to its retrospective design and small population size. The primary malignancies and treatments were also heterogenous. Furthermore, comparisons of clinical outcomes due to treatment and supportive care are limited because of differences in the medical conditions of the patients in both groups. Nevertheless, the current study will provide an impetus for future studies on the outcomes associated with metastatic cancers in the stomach.

In conclusion, metastatic tumors in the stomach may originate from various organs and show poor prognosis. Patients with solitary lesions and patients who had received any treatments survived longer after the diagnosis of metastatic cancer than patients with multiple lesions and patients who did not receive any treatments. Therefore, proper treatment with careful consideration about the characteristics of the primary tumors can increase the survival period in patients with metastatic tumor to the stomach, especially in cases with solitary metastatic lesions in endoscopic findings.
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![Endoscopic appearance of metastatic tumors in the stomach. (A) Resembling submucosal tumors due to bladder cancer. (B) Resembling early primary gastric cancer due to lung adenocarcinoma. (C-F) Resembling advanced gastric cancer: (C) Type 1, due to renal cell carcinoma; (D) Type 2, due to choriocarcinoma; (E) Type 3, due to pulmonary squamous cell carcinoma; (F) Type 4, due to ovarian cancer.](gnl-09-615f1){#f1-gnl-09-615}

![Kaplan-Meier survival curves of (A) patients who underwent chemotherapy, surgery, or radiotherapy versus patients who underwent conservative treatment (p\<0.001); and (B) patients with solitary versus multiple tumors (p=0.047).](gnl-09-615f2){#f2-gnl-09-615}

###### 

Baseline Characteristics of the Study Patients with Metastatic Tumors in the Stomach (N=37)

  Variable                     Value
  ---------------------------- -------------------
  Sex                          
   Male                        21 (56.8)
   Female                      16 (43.2)
  Age, yr                      57.0 (49.5--61.0)
  ECOG performance status      
   0                           3 (8.1)
   1                           11 (29.7)
   ≥2                          23 (62.2)
  Main symptom                 
   Gastrointestinal bleeding   12 (32.4)
   Abdominal pain              6 (16.2)
   Dysphagia                   3 (8.1)
   Vomiting                    2 (5.4)
   None                        14 (37.8)
  Location                     
   Body                        22 (59.5)
   Antrum                      3 (8.1)
   Cardia                      4 (10.8)
   Fundus                      5 (13.5)
   Whole stomach               3 (8.1)
  No. of lesions               
   Solitary                    23 (62.2)
   Multiple                    14 (37.8)
  Histological type            
   Melanoma                    10 (27.0)
   Adenocarcinoma              9 (24.3)
   Squamous cell carcinoma     8 (21.6)
   Renal cell carcinoma        3 (8.1)
   Small cell carcinoma        2 (5.4)
   Other                       5 (13.5)

Data represent the number of patients (%) or median (interquartile range).

ECOG, Eastern Cooperative Oncology Group.

###### 

Site of the Primary Tumors in the Study Patients (N=37)

  Primary tumor            No. (%)
  ------------------------ -----------
  Malignant melanoma       10 (27.0)
  Lung                     7 (18.9)
  Breast                   5 (13.5)
  Gastrointestinal tract   
   Esophagus               3 (8.1)
   Colorectum              2 (5.4)
  Genitourinary tract      
   Ovary                   3 (8.1)
   Kidney                  3 (8.1)
   Bladder                 1 (2.7)
  Choriocarcinoma          1 (2.7)
  Head/neck                1 (2.7)
  Neuroblastoma            1 (2.7)

ECOG, Eastern Cooperative Oncology Group.

###### 

Endoscopic Appearance of Metastatic Tumors in the Stomach (N=37)

  Endoscopic appearance               No. (%)
  ----------------------------------- -----------
  Resembling submucosal tumors        12 (32.4)
  Resembling primary gastric cancer   
   Resembling early cancer            7 (18.9)
   Resembling advanced cancer         
    Type 1                            7 (18.9)
    Type 2                            2 (5.4)
    Type 3                            5 (13.5)
    Type 4                            4 (10.8)

Type 1, a polypoid tumor; Type 2, an ulcerated tumor with sharply demarcated margins; Type 3, an ulcerated tumor without definite borders; Type 4, diffusely infiltrating tumor.

###### 

Summary of the Characteristics of the 37 Patients in the Study Series with Metastatic Tumors in the Stomach

  No.   Sex   Age, yr   Symptom          No. of lesions   Primary site         Location        Treatment         Gross appearance   Histologic type     Outcome   Overall survival, mo   Survival after metastasis to stomach, mo
  ----- ----- --------- ---------------- ---------------- -------------------- --------------- ----------------- ------------------ ------------------- --------- ---------------------- ------------------------------------------
  1     M     47        None             Multiple         Malignant melanoma   Cardia          Supportive care   SMT                Melanoma            Dead      29                     8
  2     M     55        Abdominal pain   Multiple         Malignant melanoma   Fundus          Supportive care   EGC                Melanoma            Dead      12                     1
  3     F     56        None             Solitary         Malignant melanoma   Body            Surgery+RT        AGC1               Melanoma            Dead      85                     10
  4     M     65        Abdominal pain   Multiple         Malignant melanoma   Body            Supportive care   SMT                Melanoma            Dead      79                     2
  5     F     80        GI bleeding      Solitary         Malignant melanoma   Body            Supportive care   AGC1               Melanoma            Dead      144                    25
  6     M     59        Abdominal pain   Multiple         Malignant melanoma   Fundus          Chemo             SMT                Melanoma            Dead      2                      1
  7     F     44        Abdominal pain   Multiple         Malignant melanoma   Whole stomach   Chemo             SMT                Melanoma            Dead      2                      2
  8     F     53        GI bleeding      Solitary         Malignant melanoma   Fundus          Chemo             AGC1               Melanoma            Dead      4                      4
  9     F     55        None             Multiple         Malignant melanoma   Body            Supportive care   SMT                Melanoma            Dead      1                      1
  10    M     56        Abdominal pain   Multiple         Malignant melanoma   Body            Supportive care   SMT                Melanoma            Dead      1                      1
  11    M     44        Abdominal pain   Solitary         Lung                 Body            Surgery           AGC3               Squamous cell       Dead      60                     30
  12    M     55        GI bleeding      Solitary         Lung                 Body            Surgery           SMT                Small cell ca       Dead      18                     11
  13    F     50        None             Multiple         Lung                 Whole stomach   Chemo             EGC1               Epithelioid tumor   Dead      1                      0
  14    M     60        GI bleeding      Multiple         Lung                 Body            Supportive care   AGC3               Squamous cell ca    Dead      32                     2
  15    M     53        Dysphagia        Solitary         Lung                 Body            Supportive care   EGC1               Adenocarcinoma      Dead      6                      6
  16    M     58        None             Multiple         Lung                 Body            Supportive care   AGC3               Squamous cell       Dead      1                      1
  17    M     59        None             Multiple         Lung                 Body            Supportive care   SMT                Squamous cell       Dead      5                      4
  18    M     61        GI bleeding      Solitary         Kidney               Fundus          Supportive care   AGC1               Renal cell          Dead      4                      1
  19    M     55        None             Multiple         Kidney               Body            Supportive care   SMT                Renal cell          Dead      1                      1
  20    M     56        Abdominal pain   Multiple         Kidney               Body            Supportive care   SMT                Renal cell          Alive     1                      1
  21    M     47        None             Multiple         Head/neck            Cardia          Supportive care   EGC1               Small cell          Dead      16                     2
  22    M     59        None             Multiple         Esophagus            Body            Supportive care   AGC2               Squamous cell       Dead      9                      7
  23    M     63        GI bleeding      Solitary         Esophagus            Antrum          Supportive care   AGC4               Squamous cell       Dead      1                      30
  24    M     58        Dysphagia        Multiple         Esophagus            Cardia          Surgery+chemo     EGC1               Squamous cell       Alive     16                     16
  25    M     66        Abdominal pain   Solitary         Esophagus            Body            Surgery+chemo     SMT                Squamous cell       Alive     13                     13
  26    M     57        GI bleeding      Solitary         Colorectum           Whole stomach   Supportive care   SMT                Adenocarcinoma      Dead      1                      54
  27    F     66        GI bleeding      Multiple         Colorectum           Body            Supportive care   SMT                Adenocarcinoma      Dead      3                      24
  28    F     47        GI bleeding      Solitary         Choriocarcinoma      Body            Supportive care   AGC1               Choriocarcinoma     Dead      1                      6
  29    F     31        Vomiting         Solitary         Breast               Body            Chemo             EGC                Adenocarcinoma      Dead      15                     43
  30    F     64        Vomiting         Multiple         Breast               Antrum          Chemo             AGC4               Adenocarcinoma      Dead      9                      77
  31    F     51        Dysphagia        Solitary         Breast               Fundus          Supportive care   EGC                Adenocarcinoma      Dead      3                      54
  32    F     61        None             Multiple         Breast               Body            Chemo             SMT                Adenocarcinoma      Alive     21                     273
  33    F     49        Abdominal pain   Solitary         Bladder              Body            Chemo             AGC1               Adenocarcinoma      Dead      11                     12
  34    F     45        None             Solitary         Ovary                Body            Supportive care   AGC4               Adenocarcinoma      Dead      13                     67
  35    F     60        Abdominal pain   Solitary         Ovary                Body            Supportive care   AGC4               Adenocarcinoma      Dead      1                      46
  36    F     64        None             Solitary         Ovary                Antrum          Chemo             AGC3               Adenocarcinoma      Dead      7                      37
  37    F     2         GI bleeding      Solitary         Neuroblastoma        Cardia          Supportive care   AGC1               Neuroblastoma       Dead      2                      9

M, male; SMT, resembling submucosal tumor; EGC, resembling early gastric cancer; F, female; RT, radiotherapy; AGC, resembling advanced gastric cancer; Chemo, chemotherapy; GI, gastrointestinal; ca, cancer.

###### 

Clinicopathologic Features of Metastatic Tumors in the Stomach (N=37)

  Clinicopathologic feature                                  Value
  ---------------------------------------------------------- ------------------
  Treatment method of primary cancer                         
   Surgery                                                   2 (5.4)
   Surgery+chemotherapy                                      13 (35.1)
   Surgery+radiotherapy                                      1 (2.7)
   Chemotherapy                                              9 (24.3)
   Chemotherapy+radiotherapy                                 2 (5.4)
   Radiotherapy                                              1 (2.7)
   Conservative                                              5 (13.5)
  Treatment method of metastatic cancer                      
   Surgery                                                   2 (5.4)
   Chemotherapy                                              6 (16.2)
   Surgery+chemotherapy                                      4 (10.8)
   Conservative                                              25 (67.6)
  Dead                                                       33 (89.2)
  Alive                                                      4 (10.8)
  Survival after diagnosis of primary cancer, mo             18.0 (6.0--18.0)
  Time span, mo[\*](#tfn7-gnl-09-615){ref-type="table-fn"}   14.0 (0.5--48.0)
  Survival after diagnosis of metastatic cancer, mo          3.0 (1.0--11.0)

Data represent the numbers of patients (%) or median (interquartile range).

Time between the diagnosis of the primary tumor and metastatic lesions.

###### 

Comparisons of the Clinical Features of Solitary and Multiple Lesions in the Study Cohort (N=37)

  Clinical feature                                            Solitary (n=23)     Multiple (n=14)     p-value
  ----------------------------------------------------------- ------------------- ------------------- ---------
  Sex                                                                                                 0.471
   Male                                                       12                  9                   
   Female                                                     11                  5                   
  Age, yr                                                     58.0 (47.0--60.0)   55.5 (52.2--61.7)   0.590
  Site of primary tumor                                                                               0.023
   Melanoma                                                   3                   7                   
   Nonmelanoma                                                20                  7                   
  Endoscopic appearance                                                                               0.065
   Resembling SMT                                             4                   7                   
   Resembling early cancer                                    4                   3                   
   Resembling advanced cancer                                 15                  4                   
  Treatment                                                   9                   3                   0.306
  Death                                                       20                  13                  1.000
  Time span, mo[\*](#tfn10-gnl-09-615){ref-type="table-fn"}   28.0 (1.0--51.0)    12.0 (0--38.5)      0.412
  Survival after diagnosis of primary tumor, mo               32.0 (9.0--54.0)    13.0 (2.0--30.0)    0.445
  Survival after diagnosis of metastatic tumor, mo            7.0 (2.0--13.0)     2.0 (1.0--6.0)      0.047

Data represent the numbers of patients or median (interquartile range).

SMT, resembling submucosal tumor.

Time between the diagnosis of the primary tumor and metastatic lesions.

[^1]: Ga Hee Kim and Ji Yong Ahn contributed equally to this work as first authors.
